SSCP Cardiology PSN (@sscpCardpsn) header
SSCP Cardiology PSN (@sscpCardpsn) profile picture

The official Cardiology PSN @SSCP_KSA Official Email: [email protected] | المجموعة التخصصية لعلاجات أمراض القلب | الجمعية السعودية للصيدلة السريرية

Joined October 2020
Photo by SSCP Cardiology PSN (@sscpCardpsn)Photo by SSCP Cardiology PSN (@sscpCardpsn)Photo by SSCP Cardiology PSN (@sscpCardpsn)Photo by SSCP Cardiology PSN (@sscpCardpsn)Photo by SSCP Cardiology PSN (@sscpCardpsn)Photo by SSCP Cardiology PSN (@sscpCardpsn)Photo by SSCP Cardiology PSN (@sscpCardpsn)Photo by SSCP Cardiology PSN (@sscpCardpsn)Photo by SSCP Cardiology PSN (@sscpCardpsn)Photo by SSCP Cardiology PSN (@sscpCardpsn)
Long-term LDL-C management made simpler for patients with HeFH! 💡 Phase 3 data for Inclisiran—an siRNA targeting hepatic PCSK9 synthesis—demonstrated robust and sustained LDL-C reduction with an infrequent dosing schedule and a favorable safety profile. An encouraging approach to long-term LDL-C management through targeted siRNA therapy.
2
283
Promising Phase 3 data for Lerodalcibep in Heterozygous Familial Hypercholesterolemia (HeFH)! 🧬 As a novel small fusion protein targeting PCSK9, monthly administration demonstrated significant and sustained LDL-C reduction, with a safety profile comparable to placebo. An encouraging step forward in the development of long-acting PCSK9-targeted therapies for HeFH.
203
Promising findings from the FOURIER trial evaluating evolocumab in patients with established ASCVD! Adding the PCSK9 inhibitor evolocumab to statin therapy significantly reduced LDL-C levels and lowered the risk of major cardiovascular events, with a safety profile comparable to placebo. A landmark trial supporting the benefits of intensive LDL-C lowering in patients with established ASCVD.
2
3
20,210
Alirocumab demonstrates promising results in heterozygous familial hypercholesterolemia (HeFH), delivering sustained LDL-C reductions and helping more patients achieve recommended LDL-C targets despite ongoing lipid-lowering therapy. 🧬 An encouraging advance in the management of HeFH and long-term cardiovascular risk.
1
2
553
Promising Phase 2 data for Lepodisiran in adults with elevated Lp(a)! 🧬 By targeting hepatic Lp(a) production using siRNA technology, Lepodisiran demonstrated potent and sustained reductions in Lp(a) levels, with a favorable safety profile. An encouraging step forward in the development of targeted therapies for Lp(a) and future cardiovascular risk management.
1
5
1
642
Promising Phase 2 results for Olpasiran in patients with ASCVD and elevated Lp(a). Using siRNA technology to target LPA expression in hepatocytes, Olpasiran demonstrated potent and sustained reductions in Lp(a) levels, with a favorable safety profile. 🧬 An encouraging step forward in the development of targeted therapies for Lp(a) and future cardiovascular care.
5
2
657
في اليوم العالمي لفرط كوليسترول الدم العائلي (FH) 🫀 نرفع الوعي بأهمية الفحص المبكر، والالتزام بالعلاج، واتباع نمط حياة صحي للمساعدة في تقليل مخاطر أمراض القلب والأوعية الدموية. اعرف تاريخك العائلي، افحص مبكرًا، واعتنِ بصحة قلبك. #KnowFH #FHAwarenessDay #FamilialHypercholesterolemia.
4
6
710
في اليوم العالمي لفرط كوليسترول الدم العائلي (FH) 🫀 نرفع الوعي بأهمية الفحص المبكر، والالتزام بالعلاج، واتباع نمط حياة صحي للمساعدة في تقليل مخاطر أمراض القلب والأوعية الدموية. اعرف تاريخك العائلي، افحص مبكرًا، واعتنِ بصحة قلبك. #KnowFH #FHAwarenessDay #FamilialHypercholesterolemia.
2
3
569
🐟 Fish oil is back in the spotlight. The PISCES trial explores whether omega-3 supplementation can improve cardiovascular outcomes in patients undergoing maintenance hemodialysis.
🤖 Made with AI
1
5
941
SSCP Cardiology PSN retweeted
🫀 Can cardiac myosin inhibition benefit adolescents with obstructive HCM? The phase 3 trial of mavacamten provides encouraging evidence for reducing LVOT obstruction while maintaining a favorable safety profile!
🤖 Made with AI
6
6
1,617
SSCP Cardiology PSN retweeted
🫀Not every lifelong therapy needs to be lifelong. #SMARTDECISION evaluates whether β-blockers can be safely discontinued after myocardial infarction in selected patients. A modern answer to a legacy practice. Take a look!
3
3
506
SSCP Cardiology PSN retweeted
🫀 #VESALIUSCV expands the role of #PCSK9i into high-risk primary prevention. 🏆 Among 6,129 high-risk patients, evolocumab significantly reduced first CV events: 📉 3-point MACE: 8.0% → 6.2% (ARR 1.8%, NNT 56) 📉 4-point MACE: 16.2% → 13.4% (ARR 2.8%, NNT 36)
1
1
337
🫀 Can cardiac myosin inhibition benefit adolescents with obstructive HCM? The phase 3 trial of mavacamten provides encouraging evidence for reducing LVOT obstruction while maintaining a favorable safety profile!
🤖 Made with AI
6
6
1,617
🫀Not every lifelong therapy needs to be lifelong. #SMARTDECISION evaluates whether β-blockers can be safely discontinued after myocardial infarction in selected patients. A modern answer to a legacy practice. Take a look!
3
3
506
🫀 #VESALIUSCV expands the role of #PCSK9i into high-risk primary prevention. 🏆 Among 6,129 high-risk patients, evolocumab significantly reduced first CV events: 📉 3-point MACE: 8.0% → 6.2% (ARR 1.8%, NNT 56) 📉 4-point MACE: 16.2% → 13.4% (ARR 2.8%, NNT 36)
1
1
337
LOVE CARDIOLOGY? WE WANT YOU! ❤️ Become a volunteer with the SSCP Cardiology PSN and be part of a community dedicated to education, innovation, and excellence in cardiovascular care. 🚀 Learn 🤝 Connect ⭐ Lead ❤️ Make an Impact Sign up! forms.gle/wbGvBoUX3H7p2NsMA
5
1
29
28,371
As we conclude today’s scientific meeting, we extend our sincere appreciation to the organizing team whose dedication, professionalism, and teamwork were instrumental in delivering a successful and impactful program. Thank you for your efforts in making this event a success! 🫀
1
9
1,142
The Junior Pharmacist Interactive Engagement Challenge featured an interactive audience questions competition, fostering active participation and knowledge exchange, and was led by Dr. Reem Bahmaid and Dr. Mahasen Alharbi.
1
1
1
762
Honoring the First and Second Place Winners of the Junior Pharmacist Interactive Engagement Challenge! 🥇Abdulrahman Al-Sulea 🥈Omar Alshatry
1
7
813
The Symposium for the GOLDEN Sponsor was delivered by Dr. Yaser Nemshah, highlighting key perspectives and insights relevant to current and emerging therapeutic approaches in the management of cardiac amyloidosis🫀.
1
1
524
Honoring Dr. Yaser Nemshah in recognition of his valuable contribution. We extend our sincere appreciation for his role in enriching the scientific program.
1
404